Save time and jump to the most important pieces.
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company's Vice President of Research & Development and Clinical Translation since September 2021. His previous role was Head of Clinical Translation from 2020 to 2021, having joined the Company in 2016 as Executive Director of Research and Development (R&D). "We are delighted to name
– Frank Tirelli Will Serve as Chair of Kiromic's Audit Committee – – Dr. Reeves Brings Deep Biopharmaceutical, Regulatory, and Clinical Expertise to Board Role – Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces the appointment of two outside directors to the Company's Board of Directors: Frank Tirelli and Karen Reeves, M.D. Frank Tirelli was appointed to the Company's Board effective on January 28,
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP) — Expansion of in-house cGMP manufacturing facility to provide support to the Company's clinical trials. Therapeutic doses expected to be ready for first in-human dosing in 3Q-2021. — Mr. Ignacio Núñez, a 20-year industry veteran in global operations and manufacturing, is joining the Kiromic team to take the company to the next level and to scale up cGMP manufacturing capabilities internally. Kiromic is an immuno-oncology company using Artificial Intelligence (AI) to identify critical markers in solid tumors to develop Allogeneic CAR-T cell therapy. Kiromic’s CAR-T technology addresses critical efficacy and safet
10-Q - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D - Kiromic Biopharma, Inc. (0001792581) (Subject)
SC 13D/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
Recent Corporate Highlights Include: New Leadership Appointed at the Company, Board of Director Level Completed Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell Platform Progressed a Master Cell Bank Strategy for Retro-viral Vector (RVV) Production Enhanced Kiromic's Diamond AI™ Mediated Pooled Donor Gamma Delta T Cell Banking Technology Expansion and Redesign of In-house cGMP Manufacturing Facility DIAMOND®AI 2.0 New Component NOEMI (NeurO Evolutive) Machine Learning Enabled Antibody Design) Designed to Dramatically Reduce Time and Cost of CAR-T Cell Therapy Development Cash Position $15,123,100 as of March 31, 2022 Kiromic BioPh
Highlights Include Company's Progress in the Following Areas: Advances in the Research, Development, and Manufacturing Processes of the ALEXIS Gamma Delta T cell Platform Key Hires in Research & Development, Clinical Translational Medicine and Clinical Trial Preparation Completion of Approximately 90% of In-house cGMP Facility Expansion and Redesign Launch of DIAMOND® Artificial Intelligence (AI) 2.0 Platform for Identification and Selection of Immunotherapy Targets, which Now Includes Nearly Two Billion Data Points Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artific
Kiromic Biopharma, Inc. (NASDAQ:KRBP), a pioneer in immuno oncology cellular therapy in solid tumors, is pleased to announce it has completed the acquisition of InSilico Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005822/en/http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire)">SpliceSeq, http://bioinformatics.mdanderson.org/main/SpliceSeq:Overview (Graphic: Business Wire) InSilico Solutions is a world-class bio-informatics and artificial intelligence innovator with a long standing collaborative relationship with its clients at MD Anderson Cancer Center, Johns Hopkins School of
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. At the six-month follow-up visit, Patient 4 maintained stable disease with a 5.3% reduction in tumor size compared to the pre-treatment size. At the two-month follow-up visit, Patient 6 demonstrated stable disease with no new lesions detected and no si
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient treated in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. In this patient, the tumor size was reduced by approximately 27% compared with the pre-treatment size, and no new sites of disease were identified. As a result, the progression-free survival (PFS) has reached 10 months with
Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The UACC is one of the 57 NCI-Designated Comprehensive Cancer Centers in the U.S. Dr. Ricklie Ann Julian, Assistant Professor of Medicine at UACC, will serve as Principal Investigator at the site. "We are delighted to partner with UACC, expanding our Deltace
Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares increased by 23.7% to $0.04 during Wednesday's after-market session. Trading volume for this security closed at 3.2 million, accounting for 94.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million. TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 15.55% to $1.04. The company's market cap stands at $2.1 million. Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 14.94% to $0.01. Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 11.45% to $1.46. Today's trading volume for this security ended up closing at 582.8K shares, which i
Monday's session saw 175 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Pfizer (NYSE:PFE). The smallest company by market cap to set a new 52-week low was Kiromic BioPharma (NASDAQ:KRBP). Tenon Medical (NASDAQ:TNON) made the largest move down on the session, with shares plummeting 38.98% to reach its 52-week low. Revance Therapeutics (NASDAQ:RVNC) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Stocks that set new 52-week lows on Monday are as follows: Pfizer (NYSE:PFE) shares moved down 1.71% on Monday to hit a new 52-week low of $33.54, drif
On Thursday, 283 companies set new 52-week lows. 52-Week Low Highlights: The largest company by market cap to set a new 52-week low was Pfizer (NYSE:PFE). Blue Star Foods (NASDAQ:BSFC) was the smallest company when considering market cap to set a new 52-week low. Edible Garden AG (NASDAQ:EDBL) made the largest move down on the session, with shares plummeting 34.15% to reach its 52-week low. Almacenes Exito (NYSE:EXTO) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The following stocks created new 52-week lows on Thursday: Pfizer (NYSE:PFE) shares made a new 52-week low of $34.04 on Thursday. The stock was down 0.74% for the day. Walt Disney